UNSPSC 51151525: Furtrethonium iodide

This classification denotes a cholinergic agonist with the molecular formula C8H14NO.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D064NLD7G, chemically known as 2-furanmethanaminium, n,n,n-trimethyl-, iodide (9ci) but generally known as furtrethonium iodide, which bears US NIH Compound Identifier 10937. European Medicines Agency schedules Furtrethonium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07854MIG. The term FURTRETHONIUM IODIDE is an International Non-Proprietary Name.

Most nations schedule furtrethonium iodide under HS 29321900 and SITC 51569. As of Q4 2014, FURTRETHONIUM IODIDE remains the US FDA Preferred Term for this commodity. Furtrethonium iodide bears US NLM identifiers UMLS ID C0118398 and NCI Concept Code C76041. SMILES: I.o1c(C[N](C)(C)C)ccc1.

UNSPSC 51151525 Furtrethonium iodide is a Commodity code that shows a material disconnect between its nominal scope and the work actually being solicited under it by state and local buyers. Recent opportunities posted under this code involve naloxone procurement and pharmaceutical direct-to-manufacturer contracting initiatives, neither of which aligns with furtrethonium iodide as a pharmaceutical ingredient. The code sees minimal recent activity, and the posted solicitations appear to reflect miscoding rather than genuine demand for the narrowly defined commodity the code describes.

The two recent opportunities in the source span different procurement instruments and issuing bodies. Seminole County, Florida released an IFB (Solicitation Number IFB60459723LAS) in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) in April 2026 to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from vendors with direct contracting experience for self-insured employers and government health plans. Given the absence of genuine procurement activity under the furtrethonium iodide code itself and the categorical mismatch between the code's definition and the posted opportunities, firms evaluating this code should verify taxonomy assignments on specific RFPs and RFQs before committing pursuit resources.